Lung DiseasesNCT01140685
Analysis of Anti-inflammatory and Antioxidant Pathways in Lung Diseases by Haem Oxygenase-1 (HO-1) in Induced Sputum and Carbon Monoxide (CO) in Exhaled Air
An observational study of Lung Diseases, run by Tel-Aviv Sourasky Medical Center.
Trial summary
This work will focus on the anti-inflammatory and antioxidant pathways in lung diseases by measuring HO-1 in induced sputum and CO in exhaled air in cases of four respiratory diseases, asthma, chronic obstructive pulmonary disease (COPD), occupational lung diseases (OLD) and interstitial lung disease (ILD). Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Lung Diseases
- How many people
- 70 participants
- Where
- No sites listed yet
- Study dates
- Dec 2009to Sep 2010
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Fifty adult male and female patients who had been diagnosed with one or more of the four study diseases and referred for sputum induction to the Pulmonary Laboratory in the Tel-Aviv Sourasky Medical Center will be enrolled
Who may be able to join
- Male and female
- Ages >/= 18 years
- Diagnosed with one or more lung diseases
- Referred for sputum induction to the Pulmonary Laboratory in the Tel-Aviv Sourasky Medical Center
Who cannot join
None listed.
About this study
This work will focus on the anti-inflammatory and antioxidant pathways in lung diseases by measuring HO-1 in induced sputum and CO in exhaled air in cases of four respiratory diseases, asthma, chronic obstructive pulmonary disease (COPD), occupational lung diseases (OLD) and interstitial lung disease (ILD).
- Conditions
- Lung Diseases
- Keywords
- mucus-stimulated (induced sputum), lung disease (asthma, COPD, ILD and OLD), HO-1 (heme oxigenase-1), oxidative stress, CO (carbon monoxide), The oxidative stress in lung diseases
- Medical subject headings
- Lung Diseases, Asthma, Pulmonary Disease, Chronic Obstructive, Lung Diseases, Interstitial
What is being measured
The primary outcome is the main question the study is designed to answer.
exhaled CO levels
Measured: 2010-2011
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Jun 2010 (estimated)
- Study startDec 2009
- Primary completionSep 2010 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lung DiseasesStudies of the same condition, open and under way.
- More trials run by Tel-Aviv Sourasky Medical CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 70 participants (actual)
Sponsor and investigators
- Lead sponsor
- Tel-Aviv Sourasky Medical Center
- Sponsor type
- Other government
- Investigators
- Elizabeth Fierman, PHD, Principal investigator, Tel Aviv Sorasky Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01140685
- Sponsor's protocol ID
- TASMC-10-LF-669-CTIL
- Status last verified
- Mar 2010
- First submitted
- 17 Feb 2010
- Last updated
- 9 Jun 2010
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 Jun 2010. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Analysis of Anti-inflammatory and Antioxidant Pathways in Lung Diseases by Haem Oxygenase-1 (HO-1) in Induced Sputum and Carbon Monoxide (CO) in Exhaled Air
- ClinicalTrials.gov ID
- NCT01140685
- Acronym / sponsor ID
- TASMC-10-LF-669-CTIL
- Conditions
- Lung Diseases
- Keywords
- mucus-stimulated (induced sputum), lung disease (asthma, COPD, ILD and OLD), HO-1 (heme oxigenase-1), oxidative stress, CO (carbon monoxide), The oxidative stress in lung diseases
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 70 participants (actual)
- Lead sponsor
- Tel-Aviv Sourasky Medical CenterOther government
- Study start
- Dec 2009
- Primary completion
- Sep 2010 (estimated)
- First posted
- 9 Jun 2010 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This work will focus on the anti-inflammatory and antioxidant pathways in lung diseases by measuring HO-1 in induced sputum and CO in exhaled air in cases of four respiratory diseases, asthma, chronic obstructive pulmonary disease (COPD), occupational lung diseases (OLD) and interstitial lung disease (ILD).
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Fifty adult male and female patients who had been diagnosed with one or more of the four study diseases and referred for sputum induction to the Pulmonary Laboratory in the Tel-Aviv Sourasky Medical Center will be enrolled
Key inclusion criteria (4 listed)
- Male and female
- Ages >/= 18 years
- Diagnosed with one or more lung diseases
- Referred for sputum induction to the Pulmonary Laboratory in the Tel-Aviv Sourasky Medical Center
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
exhaled CO levels
Time frame: 2010-2011
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Jun 2010.
Related trials for Lung Diseases
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Elizabeth Fierman, PHD principal investigator
Tel Aviv Sorasky Medical Center
Questions about this trial
What is this clinical trial studying?
An observational study of Lung Diseases, run by Tel-Aviv Sourasky Medical Center.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 9 Jun 2010. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
exhaled CO levels (time frame: 2010-2011). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jun 2010.